meropenem kabi 500mg prášek pro injekční/infuzní roztok
fresenius kabi s.r.o., praha array - 14052 trihydrÁt meropenemu - prášek pro injekční/infuzní roztok - 500mg - meropenem
oxaliplatin kabi 5mg/ml koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha array - 10588 oxaliplatina - koncentrát pro infuzní roztok - 5mg/ml - oxaliplatina
paclitaxel kabi 6mg/ml koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha array - 13163 paklitaxel - koncentrát pro infuzní roztok - 6mg/ml - paklitaxel
stimufend
fresenius kabi deutschland gmbh - pegfilgrastim - neutropenie - imunostimulancia, faktory stimulující kolonie - zkrácení doby trvání neutropenie a incidence febrilní neutropenie u dospělých pacientů léčených cytotoxickou chemoterapií pro malignitu (s výjimkou chronické myeloidní leukémie a myelodysplastických syndromů).
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
isolyte infuzní roztok
fresenius kabi s.r.o., praha array - 1306 trihydrÁt natrium-acetÁtu; 1322 chlorid sodnÝ; 1174 chlorid draselnÝ; 856 hexahydrÁt chloridu hoŘeČnatÉho - infuzní roztok - elektrolyty
amikacin fresenius kabi 5mg/ml infuzní roztok
fresenius kabi s.r.o., praha array - 3299 amikacin-disulfÁt - infuzní roztok - 5mg/ml - amikacin
anidulafungin fresenius kabi 100mg prášek pro koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha ČeskÁ republika - 15802 anidulafungin - prášek pro koncentrát pro infuzní roztok - 100mg - anidulafungin
ertapenem fresenius kabi 1g prášek pro koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha array - 16593 sodnÁ sŮl ertapenemu - prášek pro koncentrát pro infuzní roztok - 1g - ertapenem
fingolimod fresenius kabi 0,5mg tvrdá tobolka
fresenius kabi s.r.o., praha array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod